Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
Authors
Keywords
-
Journal
Future Oncology
Volume 15, Issue 9, Pages 929-941
Publisher
Future Medicine Ltd
Online
2019-01-29
DOI
10.2217/fon-2018-0745
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
- (2018) Jason Zhu et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.
- (2018) Chung-Han Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update
- (2017) Masatoshi Kudo ONCOLOGY
- Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
- (2017) Alessandro Leonetti et al. Therapeutics and Clinical Risk Management
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma
- (2016) Sung Hee Lim et al. Asia-Pacific Journal of Clinical Oncology
- Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor–Directed Therapies Fail
- (2016) Gabriel G. Malouf et al. Journal of Oncology Practice
- A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma
- (2015) Ravindran Kanesvaran et al. Clinical Genitourinary Cancer
- Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma
- (2015) Viktor Grünwald et al. EUROPEAN UROLOGY
- International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
- (2015) Ariana Znaor et al. EUROPEAN UROLOGY
- Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma
- (2015) Francesco Massari et al. Expert Review of Anticancer Therapy
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions
- (2014) Abhishek Tripathi et al. BIODRUGS
- A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer
- (2014) Thomas Powles et al. EUROPEAN JOURNAL OF CANCER
- Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma
- (2014) Guru Sonpavde et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- Differentiating mTOR inhibitors in renal cell carcinoma
- (2013) Sumanta K. Pal et al. CANCER TREATMENT REVIEWS
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma
- (2012) Christoph Seidel et al. EUROPEAN JOURNAL OF CANCER
- Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science
- (2012) Camillo Porta et al. Expert Review of Anticancer Therapy
- Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
- (2011) D. Y. Heng et al. ANNALS OF ONCOLOGY
- Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
- (2011) Jonas Busch et al. BMC CANCER
- ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
- (2011) Jean-Jacques Patard et al. EUROPEAN UROLOGY
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
- (2011) Ilya Tsimafeyeu et al. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
- Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2010) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started